MX2024013871A - Agentes aglutinantes 5t4 y usos de los mismos - Google Patents

Agentes aglutinantes 5t4 y usos de los mismos

Info

Publication number
MX2024013871A
MX2024013871A MX2024013871A MX2024013871A MX2024013871A MX 2024013871 A MX2024013871 A MX 2024013871A MX 2024013871 A MX2024013871 A MX 2024013871A MX 2024013871 A MX2024013871 A MX 2024013871A MX 2024013871 A MX2024013871 A MX 2024013871A
Authority
MX
Mexico
Prior art keywords
binding agents
antibodies
antibody
present disclosure
disclosure provides
Prior art date
Application number
MX2024013871A
Other languages
English (en)
Spanish (es)
Inventor
Bonnie Hammer
Jeffrey N Higaki
Seema Kantak
Charles Kaplan
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MX2024013871A publication Critical patent/MX2024013871A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024013871A 2022-05-13 2024-11-08 Agentes aglutinantes 5t4 y usos de los mismos MX2024013871A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263341944P 2022-05-13 2022-05-13
PCT/US2023/066819 WO2023220626A2 (en) 2022-05-13 2023-05-10 5t4 binding agents and uses thereof

Publications (1)

Publication Number Publication Date
MX2024013871A true MX2024013871A (es) 2024-12-06

Family

ID=88731098

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013871A MX2024013871A (es) 2022-05-13 2024-11-08 Agentes aglutinantes 5t4 y usos de los mismos

Country Status (16)

Country Link
US (1) US20250326858A1 (enExample)
EP (1) EP4522660A4 (enExample)
JP (1) JP2025518493A (enExample)
KR (1) KR20250024530A (enExample)
CN (2) CN120607619A (enExample)
AU (1) AU2023267764A1 (enExample)
CA (1) CA3252305A1 (enExample)
CL (2) CL2024003442A1 (enExample)
CO (1) CO2024015383A2 (enExample)
CR (1) CR20240489A (enExample)
DO (1) DOP2024000234A (enExample)
IL (1) IL316788A (enExample)
MX (1) MX2024013871A (enExample)
PE (1) PE20251275A1 (enExample)
TW (1) TW202400639A (enExample)
WO (1) WO2023220626A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025180472A1 (zh) * 2024-02-28 2025-09-04 惠和生物技术(上海)有限公司 单克隆抗体分子及其用途
US20260008868A1 (en) * 2024-07-05 2026-01-08 Solve Therapeutics, Inc. 5t4-binding proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596295A (en) * 2006-03-10 2013-01-25 Wyeth Corp Anti-5T4 antibodies and uses thereof
CA2959694C (en) * 2014-09-04 2023-11-21 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
CN114025797A (zh) * 2019-05-31 2022-02-08 昆士兰医学研究所理事会 抗Gal9免疫抑制性结合分子

Also Published As

Publication number Publication date
EP4522660A2 (en) 2025-03-19
PE20251275A1 (es) 2025-05-14
WO2023220626A3 (en) 2023-12-14
IL316788A (en) 2025-01-01
CL2025002572A1 (es) 2025-10-03
CL2024003442A1 (es) 2025-02-28
WO2023220626A2 (en) 2023-11-16
KR20250024530A (ko) 2025-02-18
US20250326858A1 (en) 2025-10-23
AU2023267764A1 (en) 2024-11-21
CN119546643A (zh) 2025-02-28
CR20240489A (es) 2025-01-07
CN120607619A (zh) 2025-09-09
DOP2024000234A (es) 2025-02-28
TW202400639A (zh) 2024-01-01
JP2025518493A (ja) 2025-06-17
EP4522660A4 (en) 2026-04-29
CA3252305A1 (en) 2023-11-16
CO2024015383A2 (es) 2025-02-04

Similar Documents

Publication Publication Date Title
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2023013995A (es) Conjugados de anticuerpo y antraciclina.
MX2024007724A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado
WO2021178749A3 (en) Anti-ccr8 agents
MX2022013768A (es) Conjugados anticuerpo-fármaco (adc) que comprenden un anticuerpo anti-trop-2, composiciones que comprenden dichos adc, así como métodos para fabricar y utilizar los mismos.
ZA202309516B (en) Anti-ccr8 antibodies
TW200700081A (en) Anti-ctla-4 antibody compositions
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
CR20240415A (es) MOLÉCULAS DE UNIÓN CONTRA FRa
MX2025000552A (es) Conjugados anticuerpo-fármaco
WO2023220626A3 (en) 5t4 binding agents and uses thereof
ZA202200906B (en) Anti-her2/anti-4-1bb bispecific antibody and use thereof
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
ZA202213434B (en) Anti-lilrb1 antibody and uses thereof
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
MX2024013869A (es) Conjugados anticuerpo-farmaco 5t4 y usos de los mismos
MY150643A (en) Methods and compositions for targeting hepsin
MX2025011070A (es) Conjugados de anticuerpo-farmaco dll3 y usos de estos
WO2022170008A3 (en) Anti-il1rap antibodies
MX2025006221A (es) Anticuerpos anti-tfr1 y usos de los mismos
WO2023284806A9 (zh) 特异性结合cd38、bcma和cd3的抗原结合分子及其医药用途
WO2022130318A3 (en) Antibodies against integrin alpha 11 beta 1
WO2023031943A3 (en) Cd28 shedding blocking agents
MX2023005171A (es) Composiciones y metodos para tratamiento de cancer solido.